芒果视频下载

成立于1998年，知名阿膠品牌，以藥業/酒業為主導，集研發/生產/經營/投資/管理于一體的綜合性集團公司，產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類

1998年成立的輔仁藥業集團，是一家以藥業、酒業為主導，集研發、生產、經營、投資、管理于一體的綜合性集團公司。集團(tuan)(tuan)囊括(kuo)河(he)南輔(fu)(fu)仁(ren)(ren)堂制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)南輔(fu)(fu)仁(ren)(ren)懷慶堂制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開封(feng)制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)（集團(tuan)(tuan)）有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開封(feng)豫港制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開藥(yao)(yao)(yao)(yao)(yao)(yao)集團(tuan)(tuan)（開魯(lu)）制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)南同(tong)源制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)(fu)仁(ren)(ren)醫藥(yao)(yao)(yao)(yao)(yao)(yao)科技開發有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)(fu)仁(ren)(ren)藥(yao)(yao)(yao)(yao)(yao)(yao)業(ye)(ye)集團(tuan)(tuan)醫藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)(fu)仁(ren)(ren)藥(yao)(yao)(yao)(yao)(yao)(yao)業(ye)(ye)集團(tuan)(tuan)熙德隆腫瘤藥(yao)(yao)(yao)(yao)(yao)(yao)品有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、北京遠策藥(yao)(yao)(yao)(yao)(yao)(yao)業(ye)(ye)有(you)(you)限(xian)(xian)(xian)責任公(gong)(gong)(gong)司(si)(si)、北京輔(fu)(fu)仁(ren)(ren)瑞輝生物(wu)醫藥(yao)(yao)(yao)(yao)(yao)(yao)研(yan)究院、上海(hai)輔(fu)(fu)仁(ren)(ren)醫藥(yao)(yao)(yao)(yao)(yao)(yao)研(yan)發有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、鄭(zheng)州遠策生物(wu)制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)南省宋河(he)酒(jiu)業(ye)(ye)股份有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)及上市公(gong)(gong)(gong)司(si)(si)輔(fu)(fu)仁(ren)(ren)藥(yao)(yao)(yao)(yao)(yao)(yao)業(ye)(ye)集團(tuan)(tuan)制(zhi)藥(yao)(yao)(yao)(yao)(yao)(yao)股份有(you)(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)等多家全(quan)資、控股子公(gong)(gong)(gong)司(si)(si)。

集(ji)團產(chan)品(pin)(pin)涵蓋(gai)了(le)中(zhong)西藥(yao)制(zhi)(zhi)劑、生物(wu)制(zhi)(zhi)藥(yao)、原料藥(yao)、保(bao)健食品(pin)(pin)等多個門類。2006年，隨著河南輔(fu)仁堂制(zhi)(zhi)藥(yao)有限(xian)公(gong)司成功實現(xian)上市，資本的(de)力量不僅把輔(fu)仁推(tui)向一個飛(fei)速發展(zhan)時期，其(qi)行業地位亦逐步提(ti)升(sheng)。2017年12月29日，輔(fu)仁藥(yao)業重大資產(chan)重組成功，把集(ji)團優質資產(chan)——開(kai)封制(zhi)(zhi)藥(yao)（集(ji)團）有限(xian)公(gong)司置入(ru)輔(fu)仁藥(yao)業，使輔(fu)仁藥(yao)業跨入(ru)一個新的(de)發展(zhan)階段(duan)。

“品(pin)(pin)(pin)種(zhong)為核心，并購為主(zhu)線(xian)(xian)”的早期發(fa)展戰略讓輔(fu)仁(ren)藥業(ye)集(ji)團(tuan)的產能和產品(pin)(pin)(pin)線(xian)(xian)在很短時間內飛速發(fa)展。迄今(jin)，輔(fu)仁(ren)藥業(ye)集(ji)團(tuan)已擁(yong)有(you)水針劑(ji)、凍干(gan)粉(fen)針劑(ji)、口服(fu)固(gu)體制(zhi)(zhi)(zhi)劑(ji)等(deng)20多個(ge)(ge)(ge)劑(ji)型，1000余(yu)個(ge)(ge)(ge)品(pin)(pin)(pin)種(zhong)；制(zhi)(zhi)(zhi)劑(ji)綜合產能位居(ju)全國(guo)(guo)制(zhi)(zhi)(zhi)藥行(xing)業(ye)前茅。2017新版醫保(bao)目錄(lu)輔(fu)仁(ren)藥業(ye)集(ji)團(tuan)共入(ru)(ru)選578個(ge)(ge)(ge)品(pin)(pin)(pin)種(zhong)，較2009版目錄(lu)增(zeng)(zeng)(zeng)加(jia)品(pin)(pin)(pin)種(zhong)165個(ge)(ge)(ge)，增(zeng)(zeng)(zeng)幅39.95%，其中(zhong)甲類入(ru)(ru)選364個(ge)(ge)(ge)，增(zeng)(zeng)(zeng)幅42.754%，乙類入(ru)(ru)選214個(ge)(ge)(ge)，增(zeng)(zeng)(zeng)幅35.44%。在國(guo)(guo)家(jia)衛(wei)健委正式發(fa)布(bu)《國(guo)(guo)家(jia)基(ji)本(ben)藥物目錄(lu)（2018年(nian)版）》中(zhong)，輔(fu)仁(ren)藥業(ye)集(ji)團(tuan)共有(you)阿莫西林克拉維酸鉀干(gan)混懸劑(ji)、奧美拉唑腸溶膠囊(nang)、注射用(yong)重組(zu)人干(gan)擾(rao)素α2b等(deng)262個(ge)(ge)(ge)品(pin)(pin)(pin)規榜上有(you)名，較2012版目錄(lu)增(zeng)(zeng)(zeng)加(jia)75個(ge)(ge)(ge)，增(zeng)(zeng)(zeng)幅40.11%，成(cheng)為全國(guo)(guo)入(ru)(ru)選品(pin)(pin)(pin)種(zhong)較多的制(zhi)(zhi)(zhi)藥企業(ye)之一(yi)。

輔仁藥業集團一直遵循“濟世藥為輔、惠民志在仁”的(de)企(qi)業理念，始(shi)終(zhong)貫徹“產量讓位于質量、成(cheng)本讓位于質量”的(de)質量管理方針(zhen)，本著“和而不同、化(hua)繁為簡、務實創(chuang)新、濟世惠民”的(de)企(qi)業價值觀(guan)，把“做一家實體型(xing)、科技型(xing)、國際型(xing)企(qi)業”作(zuo)為自己(ji)的(de)企(qi)業定位，兼容并蓄(xu)，尊(zun)重(zhong)規律，踐行規則。

在(zai)企業并購的同時，輔仁藥(yao)(yao)業集團投入巨資加強企業創(chuang)新(xin)(xin)平(ping)(ping)臺(tai)(tai)(tai)(tai)建設，戰略性(xing)布局鄭州技術研(yan)發(fa)(fa)和國際化(hua)合(he)作(zuo)及產業化(hua)服務平(ping)(ping)臺(tai)(tai)(tai)(tai)、北(bei)京創(chuang)新(xin)(xin)研(yan)發(fa)(fa)平(ping)(ping)臺(tai)(tai)(tai)(tai)、上海(hai)醫(yi)(yi)藥(yao)(yao)研(yan)發(fa)(fa)創(chuang)新(xin)(xin)國際合(he)作(zuo)平(ping)(ping)臺(tai)(tai)(tai)(tai)、美(mei)國新(xin)(xin)澤西、費城(cheng)研(yan)發(fa)(fa)平(ping)(ping)臺(tai)(tai)(tai)(tai)四(si)大(da)研(yan)發(fa)(fa)創(chuang)新(xin)(xin)平(ping)(ping)臺(tai)(tai)(tai)(tai)，以及中醫(yi)(yi)藥(yao)(yao)大(da)數(shu)據及人工智能中醫(yi)(yi)研(yan)發(fa)(fa)平(ping)(ping)臺(tai)(tai)(tai)(tai)，更(geng)將(jiang)在(zai)小分(fen)子化(hua)學(xue)藥(yao)(yao)、大(da)分(fen)子生物藥(yao)(yao)研(yan)發(fa)(fa)和中醫(yi)(yi)藥(yao)(yao)傳承(cheng)創(chuang)新(xin)(xin)方向同時發(fa)(fa)力(li)，開辟以研(yan)發(fa)(fa)驅(qu)動創(chuang)新(xin)(xin)的發(fa)(fa)展(zhan)新(xin)(xin)路徑(jing)。

目前，輔(fu)仁(ren)(ren)藥業集團支(zhi)持創(chuang)新(xin)研發面積達11.3萬平(ping)方米，研發創(chuang)新(xin)隊(dui)伍近1500人。同(tong)時，秉承“中國市場、輔(fu)仁(ren)(ren)平(ping)臺、全球資(zi)源(yuan)”的發展策略，輔(fu)仁(ren)(ren)藥業集團實現了(le)從“百姓藥、輔(fu)仁(ren)(ren)造”到(dao)“創(chuang)新(xin)藥、輔(fu)仁(ren)(ren)造”的可(ke)持續發展跨(kua)越，為客戶及整個社會創(chuang)造價值，健康中國，服務(wu)世界。